Evidence map›Paper›PMID 38890671›Full record

ArticleAIDS research and therapy2024

Patient-reported outcomes and experiences of migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite treatment dispensation: the 'ASAP' study.

Anish K Arora, Serge Vicente, Kim Engler, David Lessard, Edmundo Huerta, Joel Ishak, Nadine Kronfli, Jean-Pierre Routy, Joseph Cox, Benoit Lemire and 8 more

Abstract read
In one paragraph

Article in AIDS research and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Anish K AroraDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.
Serge VicenteCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
Kim EnglerCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
David LessardCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
Edmundo HuertaCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
Joel IshakCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
Nadine KronfliCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
Jean-Pierre RoutyDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
Joseph CoxDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
Benoit LemirePharmacy Department, McGill University Health Centre, Montréal, QC, Canada.
Marina KleinDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
Alexandra de PokomandyDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.
Lina Del BalsoDepartment of Medicine, Chronic Viral Illness Service, Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
Giada SebastianiCentre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Blvd - Office 3C.25, Montreal, QC, H4A 3S5, Canada.
Isabelle VedelDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.
Amélie Quesnel-ValléeDepartment of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine & Health Sciences, McGill University, Montréal, QC, Canada.
Bertrand LebouchéDepartment of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada. bertrand.lebouche@mcgill.ca.
ASAP Migrant Advisory Committee

Funding

Gilead Sciences IN-US-380-4670
6 · The paper itself

Abstract

backgroundScholars recommend providing migrants living with HIV (MLWH) with free treatment, rapidly, once linked to care to optimize their HIV-related experiences and health outcomes. Quantitative evaluations of patient-reported measures for MLWH in such models are necessary to explore the viability of these recommendations.

methodsWithin a 96-week prospective cohort study at a multidisciplinary HIV clinic, participants received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for free and rapidly following care linkage. Eight patient-reported measures were administered at weeks 4, 24, and 48: (1) mMOS-SS to measure perceived social support; (2) IA-RSS to measure internalized stigma; (3) K6 to measure psychological distress; (4) PROMIS to measure self-efficacy with treatment taking; (5) G-MISS to measure perceived compliance with clinicians' treatment plans; (6) HIVTSQ to measure treatment satisfaction; (7) CARE to measure perceived provider empathy; and (8) PRPCC to measure perceived clinician cultural competence. Linear mixed modelling with bootstrapping was conducted to identify significant differences by sociodemographics and time.

resultsAcross weeks 4, 24, and 48, results suggest that MLWH enrolled in this study experienced moderate levels of social support; elevated levels of HIV-related stigma; moderate levels of distress; high self-efficacy with daily medication self-management; great compliance with clinicians' treatment plans; high treatment satisfaction; high perceived empathy; and high perceived cultural competence. Experience of social support (i.e., mMOS-SS scores) differed significantly by birth region. Experience of HIV-related stigma (i.e., IA-RSS scores) differed significantly by birth region, age, and language. Experience of distress (i.e., K6 scores) differed significantly by sexual orientation. Experience of treatment satisfaction (i.e., HIVTSQ scores) differed significantly by birth region and age. No significant differences were identified by time for any measure.

conclusionOverall, participants expressed positive experiences around treatment and care, alongside comparably lower perceptions of social support, internalized stigma, and distress, potentially underscoring a need to embed targeted, well-funded, and accessible mental health support within HIV care models.

Indexed as

Anti-HIV AgentsHIV InfectionsPatient Reported Outcome MeasuresSocial StigmaTransients and MigrantsAdultAmidesDrug CombinationsEmtricitabineFemaleHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHumansMaleMedication AdherenceMiddle AgedAmidesAnti-HIV AgentsbictegravirDrug CombinationsEmtricitabineHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsPiperazinesPyridonesTenofovirCare experienceHIVMigrantsMultidisciplinaryPatient-reported outcomes

Identifiers

PMID38890671
PMCPMC11184703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.